Research programme: cardiovascular therapeutics - Jiangsu Nhwa Pharmaceutical
Latest Information Update: 05 Aug 2016
At a glance
- Originator Jiangsu Nhwa Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Cardiovascular disorders
Most Recent Events
- 05 Aug 2016 Investigation in Cardiovascular disorders in China (unspecified route)